Moleculin Biotech Inc. has announced that it received a notification from the Nasdaq Stock Market LLC regarding its non-compliance with the Nasdaq Listing Rule 5550(b)(1). This rule requires companies to maintain a minimum of $2.5 million in stockholders' equity. As of May 23, 2025, Moleculin Biotech does not meet this requirement, nor does it fulfill alternative criteria related to market value of listed securities or net income from continuing operations. While this notification does not immediately affect the company's listing status on the Nasdaq Capital Market, Moleculin Biotech has 45 days to submit a compliance plan. If accepted, the company could be granted an extension of up to 180 days to meet the necessary requirements. Failure to have the plan accepted could lead to an appeal process, though success is not guaranteed.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。